These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20964855)

  • 1. Methods of competing risks analysis of end-stage renal disease and mortality among people with diabetes.
    Lim HJ; Zhang X; Dyck R; Osgood N
    BMC Med Res Methodol; 2010 Oct; 10():97. PubMed ID: 20964855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical Methods for Cohort Studies of CKD: Survival Analysis in the Setting of Competing Risks.
    Hsu JY; Roy JA; Xie D; Yang W; Shou H; Anderson AH; Landis JR; Jepson C; Wolf M; Isakova T; Rahman M; Feldman HI;
    Clin J Am Soc Nephrol; 2017 Jul; 12(7):1181-1189. PubMed ID: 28242844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of pathogen-specific clinical mastitis in the first 100 days of first lactation with productive lifetime: An observational study comparing competing risks models for death and sale with the Cox model.
    Hertl JA; Schukken YH; Tauer LW; Welcome FL; Gröhn YT
    Prev Vet Med; 2023 Apr; 213():105879. PubMed ID: 36841041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of dementia in patients with end-stage renal disease under maintenance dialysis-a nationwide population-based study with consideration of competing risk of mortality.
    Kuo YT; Li CY; Sung JM; Chang CC; Wang JD; Sun CY; Wu JL; Chang YT
    Alzheimers Res Ther; 2019 Apr; 11(1):31. PubMed ID: 30967155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential mortality and the excess burden of end-stage renal disease among First Nations people with diabetes mellitus: a competing-risks analysis.
    Jiang Y; Osgood N; Lim HJ; Stang MR; Dyck R
    CMAJ; 2014 Feb; 186(2):103-9. PubMed ID: 24295857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cause-specific cumulative incidence estimation and the fine and gray model under both left truncation and right censoring.
    Geskus RB
    Biometrics; 2011 Mar; 67(1):39-49. PubMed ID: 20377575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competing Risk of Death With End-Stage Renal Disease in Diabetic Kidney Disease.
    Jiang Y; Fine JP; Mottl AK
    Adv Chronic Kidney Dis; 2018 Mar; 25(2):133-140. PubMed ID: 29580577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fine-Gray subdistribution hazard models to simultaneously estimate the absolute risk of different event types: Cumulative total failure probability may exceed 1.
    Austin PC; Steyerberg EW; Putter H
    Stat Med; 2021 Aug; 40(19):4200-4212. PubMed ID: 33969508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Is the Effect of Using a Competing-risks Estimator when Predicting Survivorship After Joint Arthroplasty: A Comparison of Approaches to Survivorship Estimation in a Large Registry.
    Cuthbert AR; Graves SE; Giles LC; Glonek G; Pratt N
    Clin Orthop Relat Res; 2021 Feb; 479(2):392-403. PubMed ID: 33105301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.
    Hruskova Z; Pippias M; Stel VS; Abad-Díez JM; Benítez Sánchez M; Caskey FJ; Collart F; De Meester J; Finne P; Heaf JG; Magaz A; Palsson R; Reisæter AV; Salama AD; Segelmark M; Traynor JP; Massy ZA; Jager KJ; Tesar V
    Am J Kidney Dis; 2019 Feb; 73(2):184-193. PubMed ID: 30122544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis and design of randomised clinical trials involving competing risks endpoints.
    Tai BC; Wee J; Machin D
    Trials; 2011 May; 12():127. PubMed ID: 21595883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vascular disease, ESRD, and death: interpreting competing risk analyses.
    Grams ME; Coresh J; Segev DL; Kucirka LM; Tighiouart H; Sarnak MJ
    Clin J Am Soc Nephrol; 2012 Oct; 7(10):1606-14. PubMed ID: 22859747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performing Survival Analyses in the Presence of Competing Risks: A Clinical Example in Older Breast Cancer Patients.
    de Glas NA; Kiderlen M; Vandenbroucke JP; de Craen AJ; Portielje JE; van de Velde CJ; Liefers GJ; Bastiaannet E; Le Cessie S
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26614095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Death Does Matter--Cancer Risk in Patients With End-Stage Renal Disease: A Nationwide Population-Based Study With Competing Risk Analyses.
    Weng SF; Chiu YH; Jan RL; Chen YC; Chien CC; Wang JJ; Chu CC
    Medicine (Baltimore); 2016 Jan; 95(3):e2512. PubMed ID: 26817891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent covariates in the proportional subdistribution hazards model for competing risks.
    Beyersmann J; Schumacher M
    Biostatistics; 2008 Oct; 9(4):765-76. PubMed ID: 18434297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of end-stage renal disease in patients with type 1 diabetes.
    Finne P; Reunanen A; Stenman S; Groop PH; Grönhagen-Riska C
    JAMA; 2005 Oct; 294(14):1782-7. PubMed ID: 16219881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounting for the Competing Risk of Death to Predict Kidney Failure in Adults With Stage 4 Chronic Kidney Disease.
    Al-Wahsh H; Tangri N; Quinn R; Liu P; Ferguson Ms T; Fiocco M; Lam Md MSc NN; Tonelli M; Ravani P
    JAMA Netw Open; 2021 May; 4(5):e219225. PubMed ID: 33944922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. causalCmprsk: An R package for nonparametric and Cox-based estimation of average treatment effects in competing risks data.
    Vakulenko-Lagun B; Magdamo C; Charpignon ML; Zheng B; Albers MW; Das S
    Comput Methods Programs Biomed; 2023 Dec; 242():107819. PubMed ID: 37774426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetes and end-stage renal disease synergistically contribute to increased incidence of cardiovascular events: a nationwide follow-up study during 1998-2009.
    Chang YT; Wu JL; Hsu CC; Wang JD; Sung JM
    Diabetes Care; 2014; 37(1):277-85. PubMed ID: 23920086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.